Literature DB >> 32707190

Chrysin rescues rat myocardium from ischemia-reperfusion injury via PPAR-γ/Nrf2 activation.

Neha Rani1, Dharamvir Singh Arya2.   

Abstract

Pharmacological strategies aimed at co-activating peroxisome proliferator-activated receptor-gamma (PPAR-γ)/nuclear factor erythroid 2-related factor 2 (Nrf2) pathway have shown promising results in alleviating myocardial injury. The aim of the study was to evaluate the role of chrysin, a PPAR-γ agonist, in ischemia-reperfusion (IR)-induced myocardial infarction (MI) in rats and to explore the molecular mechanism driving this activity. To evaluate this hypothesis, chrysin (60 mg/kg, orally), PPAR-γ antagonist (GW9662, 1 mg/kg, intraperitoneally), or both were administered to rats for 28 days. On the 29th day, one-stage ligation of left anterior descending coronary artery for 45 min followed by 60 min of reperfusion was performed. Chrysin significantly decreased infarct size and improved cardiac functions following IR-induced MI. This improvement was corroborated by augmented PPAR-γ/Nrf2 expression as confirmed by immunohistochemistry and western blotting analysis. Chrysin exhibited strong anti-oxidant property as demonstrated by increased GSH and CAT levels and decreased 8-OHdG and TBARS levels. Our findings also imply that chrysin significantly inhibited inflammatory response as validated by decreased NF-κB, IKK-β, CRP, TNF-α and MPO levels. In addition, chrysin decreased TUNEL/DAPI positivity, a marker of apoptotic response and normalized cardiac injury markers. The histopathological and ultrastructural analysis further supported the functional and biochemical outcomes, showing preserved myocardial architecture. Intriguingly, co-administration with GW9662 significantly diminished the cardioprotective effect of chrysin as demonstrated by depressed myocardial function, decreased PPAR-γ/Nrf2 expression and increased oxidative stress. In conclusion, the present study demonstrates that co-activation of PPAR-γ/Nrf2 by chrysin may be crucial for its cardioprotective effect.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chrysin; GW9662; Ischemia-reperfusion; Myocardium; Nrf2; PPAR-γ

Mesh:

Substances:

Year:  2020        PMID: 32707190     DOI: 10.1016/j.ejphar.2020.173389

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Activation of the PPARγ Prevents Ferroptosis-Induced Neuronal Loss in Response to Intracerebral Hemorrhage Through Synergistic Actions With the Nrf2.

Authors:  Chenyang Duan; Dian Jiao; Hanbin Wang; Qiaoli Wu; Weidong Men; Hua Yan; Chunhui Li
Journal:  Front Pharmacol       Date:  2022-04-20       Impact factor: 5.988

2.  VSP‑17 suppresses the migration and invasion of triple‑negative breast cancer cells through inhibition of the EMT process via the PPARγ/AMPK signaling pathway.

Authors:  Xiaotian Xu; Meng Liu; Yingying Yang; Chengqiong Wei; Xiyang Zhang; Hengzhi Song; Yuhui Wang; Xiaoqun Duan
Journal:  Oncol Rep       Date:  2020-12-30       Impact factor: 3.906

Review 3.  PPARs and Myocardial Infarction.

Authors:  Kay-Dietrich Wagner; Nicole Wagner
Journal:  Int J Mol Sci       Date:  2020-12-11       Impact factor: 5.923

4.  Downregulation of amphiregulin improves cardiac hypertrophy via attenuating oxidative stress and apoptosis.

Authors:  Mingyue Ji; Yun Liu; Zhi Zuo; Cheng Xu; Li Lin; Yong Li
Journal:  Biol Direct       Date:  2022-08-22       Impact factor: 7.173

5.  Chrysophanol exerts a protective effect against sepsis-induced acute myocardial injury through modulating the microRNA-27b-3p/Peroxisomal proliferating-activated receptor gamma axis.

Authors:  Haiyan Zhao; Yuping Wang; Xiaolin Zhu
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

Review 6.  Peroxisome Proliferator-Activated Receptor-Gamma (PPAR-ɣ): Molecular Effects and Its Importance as a Novel Therapeutic Target for Cerebral Ischemic Injury.

Authors:  Ashi Mannan; Nikhil Garg; Thakur Gurjeet Singh; Harmeet Kaur Kang
Journal:  Neurochem Res       Date:  2021-07-20       Impact factor: 3.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.